Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

BACKGROUND: Breast cancer is the most common cancer among women in China. Amplification of the Human epidermal growth factor receptor type 2 (HER2) gene is present and overexpressed in 18–20% of breast cancers and historically has been associated with inferior disease-related outcomes. There has bee...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cost Eff Resour Alloc
Egile Nagusiak: Xu, Qiaoping, Yuanyuan, Li, Jiejing, Zhu, Jian, Liu, Qingyu, Li, Lingya, Chen, Ying, Luo, Changchen, Shi, Yangling, Li, Wei, Yan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2021
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7901219/
https://ncbi.nlm.nih.gov/pubmed/33622356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-021-00264-w
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak